ReShape Lifesciences (RSLS) Competitors

Abbott Laboratories (NYSE:ABT) and ReShape Lifesciences (NASDAQ:RSLS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, community ranking, media sentiment, valuation, profitability and analyst recommendations.

Do analysts rate ABT or RSLS?

Abbott Laboratories currently has a consensus target price of $133.06, suggesting a potential downside of 1.46%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, equities analysts clearly believe Abbott Laboratories is more favorable than ReShape Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.83
ReShape Lifesciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Does the MarketBeat Community prefer ABT or RSLS?

Abbott Laboratories received 545 more outperform votes than ReShape Lifesciences when rated by MarketBeat users. Likewise, 69.90% of users gave Abbott Laboratories an outperform vote while only 66.11% of users gave ReShape Lifesciences an outperform vote.

Company	Underperform	Outperform
Abbott Laboratories	Outperform Votes 943 69.90%	Underperform Votes 406 30.10%
ReShape Lifesciences	Outperform Votes 398 66.11%	Underperform Votes 204 33.89%

Do insiders and institutionals hold more shares of ABT or RSLS?

75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 22.1% of ReShape Lifesciences shares are held by institutional investors. 1.1% of Abbott Laboratories shares are held by insiders. Comparatively, 0.1% of ReShape Lifesciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the media prefer ABT or RSLS?

In the previous week, Abbott Laboratories had 70 more articles in the media than ReShape Lifesciences. MarketBeat recorded 72 mentions for Abbott Laboratories and 2 mentions for ReShape Lifesciences. Abbott Laboratories' average media sentiment score of 1.56 beat ReShape Lifesciences' score of 0.30 indicating that Abbott Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abbott Laboratories	66 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ReShape Lifesciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is ABT or RSLS more profitable?

Abbott Laboratories has a net margin of 31.95% compared to ReShape Lifesciences' net margin of -86.36%. Abbott Laboratories' return on equity of 20.74% beat ReShape Lifesciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	31.95%	20.74%	11.19%
ReShape Lifesciences	-86.36%	-179.83%	-91.48%

Which has preferable valuation & earnings, ABT or RSLS?

Abbott Laboratories has higher revenue and earnings than ReShape Lifesciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$41.95B	5.58	$13.40B	$7.65	17.65
ReShape Lifesciences	$8.68M	0.09	-$11.39M	N/A	N/A

Which has more risk and volatility, ABT or RSLS?

Abbott Laboratories has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500.

Summary

Abbott Laboratories beats ReShape Lifesciences on 16 of the 17 factors compared between the two stocks.